Milica N. Lazarevic

Belgrade, SE, Serbia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Growth hormone restrains inflammatory activity of microglia/macrophages in CNS autoimmunity.

Growth hormone restrains inflammatory activity of microglia/macrophages in CNS autoimmunity.

Journal: Frontiers in cellular neuroscience

Published: March 11, 2026

FFAR2 activation induces IL-22-dependent intestinal immune responses to suppress CNS autoimmunity.

FFAR2 activation induces IL-22-dependent intestinal immune responses to suppress CNS autoimmunity.

Journal: EMBO molecular medicine

Published: January 20, 2026

Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor.

Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor.

Journal: International journal of molecular sciences

Published: September 30, 2025

Activation of Intestinal Type 3 Innate Lymphoid Cells and Regulatory T Cells Through Free Fatty Acid Receptor 2 Ameliorates Type 1 Diabetes in Mice.

Activation of Intestinal Type 3 Innate Lymphoid Cells and Regulatory T Cells Through Free Fatty Acid Receptor 2 Ameliorates Type 1 Diabetes in Mice.

Journal: Diabetes

Published: August 07, 2025

Changes in Adaptive Immunity in Autoimmune Diseases and Aging: Shared Features, Key Differences, and Implications for Immune Vulnerability.

Changes in Adaptive Immunity in Autoimmune Diseases and Aging: Shared Features, Key Differences, and Implications for Immune Vulnerability.

Journal: European journal of immunology

Published: July 26, 2025

Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab.

Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab.

Journal: Vaccines

Published: March 06, 2025

Amelioration of Central Nervous System Autoimmunity Through FFAR2 Agonism Is Associated With Changes in Gut Microbiota.

Amelioration of Central Nervous System Autoimmunity Through FFAR2 Agonism Is Associated With Changes in Gut Microbiota.

Journal: Brain and behavior

Published: October 17, 2024

Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator.

Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator.

Journal: Clinical and experimental immunology

Published: July 11, 2024

Anti-Neuroinflammatory Effects of a Novel Bile Acid Derivative.

Anti-Neuroinflammatory Effects of a Novel Bile Acid Derivative.

Journal: International journal of molecular sciences

Published: May 22, 2024

Brain inflammation in experimental autoimmune encephalomyelitis induced in Dark Agouti rats with spinal cord homogenate.

Brain inflammation in experimental autoimmune encephalomyelitis induced in Dark Agouti rats with spinal cord homogenate.

Journal: Immunology letters

Published: December 14, 2023

Complete Freund's adjuvant as a confounding factor in multiple sclerosis research.

Complete Freund's adjuvant as a confounding factor in multiple sclerosis research.

Journal: Frontiers in immunology

Published: December 11, 2023

Increased regulatory activity of intestinal innate lymphoid cells type 3 (ILC3) prevents experimental autoimmune encephalomyelitis severity.

Increased regulatory activity of intestinal innate lymphoid cells type 3 (ILC3) prevents experimental autoimmune encephalomyelitis severity.

Journal: Journal of neuroinflammation

Published: October 12, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026